Since CTX-009 targets tumor induced neoangiogenesis, and monoclonal antibodies that target vascular endothelial growth factor (VEGF) has been shown to extend the lives of patients with advanced colorectal cancer, testing of CTX-009 in the setting of advanced treatment refractory colorectal cancer is ...
metastatic or recurrent biliary tract cancer in the second- or third-line setting. Patients received 10 mg/kg of intravenous (IV) CTX-009 biweekly in combination with 80 mg/m2 of IV paclitaxel on days 1, 8, and 15 every 4 weeks. ...